{"title":"Incidence and characteristics of pediatric patients with Crohn's disease undergoing surgery: A cross-sectional study.","authors":"Hugo Gagnon, Marie-Frédérique Paré, Guillermo Costaguta, Marie-Catherine Turcotte, Prévost Jantchou, Laurence Chapuy, Colette Deslandres","doi":"10.1002/jpr3.70052","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Despite biological treatments reducing the burden of pediatric inflammatory bowel disease, many patients still require surgery. Data on pediatric patient characteristics and surgical incidence are limited, often based on adult studies. This study aimed to assess the characteristics of pediatric Crohn's disease (CD) at diagnosis and compare surgery rates between two periods (before and after 2019) to understand which patients require surgery.</p><p><strong>Methods: </strong>We analyzed pediatric CD patients who underwent surgery at CHU Sainte-Justine, Montreal, between 2014 and 2023. Descriptive statistics and the Mann-Whitney <i>U</i>-test were used to compare means, while Kaplan-Meier curves assessed surgery-free survival, with significance set at <i>p</i> < 0.05.</p><p><strong>Results: </strong>The overall surgery incidence was 5.2/1000 person-years. Surgery rates were lower for patients diagnosed after 2019 than before 2019 (5.6/1000 vs. 14.7/1000 person-years). There were no significant differences in age at diagnosis, CD Paris score, reason for surgery, or disease severity. Among CD patients, surgeries were more frequent before 2019 (11.5% vs. 2.8%, <i>p</i> < 0.001). The reduction in surgery rates since 2019 is likely due to earlier initiation of biologics, with a median initiation of 14 days after 2019 compared to 142 days before 2019 (<i>p</i> = 0.01).</p><p><strong>Conclusion: </strong>The reduced incidence of surgery in pediatric CD is a significant achievement. Increased use of infliximab, proactive drug monitoring, and better nonresponder management likely contribute to this improvement.</p>","PeriodicalId":501015,"journal":{"name":"JPGN reports","volume":"6 3","pages":"219-226"},"PeriodicalIF":0.0000,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12350037/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JPGN reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/jpr3.70052","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Objectives: Despite biological treatments reducing the burden of pediatric inflammatory bowel disease, many patients still require surgery. Data on pediatric patient characteristics and surgical incidence are limited, often based on adult studies. This study aimed to assess the characteristics of pediatric Crohn's disease (CD) at diagnosis and compare surgery rates between two periods (before and after 2019) to understand which patients require surgery.
Methods: We analyzed pediatric CD patients who underwent surgery at CHU Sainte-Justine, Montreal, between 2014 and 2023. Descriptive statistics and the Mann-Whitney U-test were used to compare means, while Kaplan-Meier curves assessed surgery-free survival, with significance set at p < 0.05.
Results: The overall surgery incidence was 5.2/1000 person-years. Surgery rates were lower for patients diagnosed after 2019 than before 2019 (5.6/1000 vs. 14.7/1000 person-years). There were no significant differences in age at diagnosis, CD Paris score, reason for surgery, or disease severity. Among CD patients, surgeries were more frequent before 2019 (11.5% vs. 2.8%, p < 0.001). The reduction in surgery rates since 2019 is likely due to earlier initiation of biologics, with a median initiation of 14 days after 2019 compared to 142 days before 2019 (p = 0.01).
Conclusion: The reduced incidence of surgery in pediatric CD is a significant achievement. Increased use of infliximab, proactive drug monitoring, and better nonresponder management likely contribute to this improvement.
目的:尽管生物治疗减轻了儿童炎症性肠病的负担,但许多患者仍然需要手术治疗。关于儿童患者特征和手术发生率的数据有限,通常基于成人研究。本研究旨在评估儿童克罗恩病(CD)在诊断时的特征,并比较两个时期(2019年前后)的手术率,以了解哪些患者需要手术。方法:我们分析了2014年至2023年间在蒙特利尔CHU Sainte-Justine接受手术的儿科CD患者。采用描述性统计和Mann-Whitney u检验比较均值,Kaplan-Meier曲线评估无手术生存率,显著性设为p。结果:总手术发生率为5.2/1000人年。2019年之后诊断的患者的手术率低于2019年之前(5.6/1000 vs 14.7/1000人年)。在诊断年龄、CD Paris评分、手术原因或疾病严重程度方面没有显著差异。在CD患者中,2019年之前的手术频率更高(11.5%比2.8%,p p = 0.01)。结论:降低小儿乳糜泻的手术发生率是一项重大成就。增加英夫利昔单抗的使用、积极的药物监测和更好的无反应管理可能有助于这种改善。